Medformula online pharmacy offers to buy online prescription medications, generic drugs and herbal remedies,
In our online drugstore you can find many prescription drugs with low prices and you'll get free doctor's review.

30 Jun 2011 12:35 PM

MAA For Perampanel, Eisai's New Drug For Treatment Of Epilepsy Accepted By European Medicines Agency For Review


Eisai, a Japanese pharmaceutical company, has disclosed that its Marketing Authorization Application (MAA) for a new first-in-class epilepsy drug, perampanel, had been accepted for review by the European Medicines Agency (EMA). The medication is aimed to treat the most common type of epilepsy (partial-onset seizures) and is a highly selective non-competitive AMPA-type glutamate receptor antagonist.



Epilepsy is a very common neurological condition across the globe with Europe alone believed to have 6 million people who suffer from the condition. Even in today's modern world with drugs being available for most disease forms, it is a challenge to successfully treat episodes of partial onset seizures. Although anti-epileptic drugs are prescribed to all patients with partial onset seizures, up to 30% never attain complete seizure freedom.



Professor Bernhard Steinhoff, Medical Director and Executive Chief Physician of the epilepsy clinic for adults, Kork Epilepsy Centre, Germany said:



"The acceptance of this application by the EMA is a positive step in the process towards bringing this important therapy to epilepsy patients with uncontrolled partial-onset seizures. "Uncontrolled seizures have a severe impact on patient quality of life and everyday function, so we look forward to the possibility of being able to offer epilepsy patients a new treatment option in the near future."




Three large Phase III, randomized, double-blind, placebo-controlled, dose-escalation studies in which a total of 1,480 epilepsy patients were enrolled globally have clearly demonstrated consistent safety, efficacy and tolerability results for perampanel in effective treatment of partial-onset seizures.



The primary and secondary endpoints were the same in all the studies: 50% responder rate, standard median percent seizure reduction, percentage reduction of complex partial plus secondarily generalized seizures, and evaluation for dose response.



In addition to being a potential new treatment for epilepsy, perampanel has extra benefits. Made possible by once daily dosing of perampanel, one...
Sign in, to get FREE bonus pills or check status of your order 
Call Toll-free:

1–855–444–5599

(9:00 am – 5:00 pm ET)